Propanc Biopharma (PPCB) investor relations material

Company overview and business model

• Development-stage biopharma focused on cancer treatments intended to prevent solid-tumor recurrence and metastasis in pancreatic, ovarian and colorectal cancers.

• Lead candidate PRP is an intravenous proenzyme formulation of trypsinogen and chymotrypsinogen; it remains preclinical.

• As of October 1, 2026, clinical preparation was underway; CTA submission was planned for Q4 2026, trial logistics and site initiation for Q1 2027, and a funded Phase Ib study for H1 2027.

• Planned Phase Ib study: 30–40 patients with advanced solid tumors, evaluating safety, pharmacokinetics and anti-tumor activity; completion target is within 24 months of commencement.

• PRP has FDA Orphan Drug Designation for pancreatic cancer; a request for ovarian cancer designation was denied in 2017.

Financial performance and metrics

• FY2026 revenue was $0; net loss was $18.86M versus $58.92M in FY2025, and operating cash use was $5.68M versus $0.41M.

• At June 30, 2026: cash $832,006, total assets $12.78M, current liabilities $3.35M and accumulated deficit $144.48M.

• FY2026 R&D expense rose to $625,477 from $223,721 in FY2025, mainly for PRP clinical preparation and the POP1 research program.

• Auditors and management cited substantial doubt about going concern; available cash and commitments were insufficient for obligations over the next 12 months.

Use of proceeds and capital allocation

• No proceeds are expected from selling stockholder resales; selling expenses are borne by the seller, while registration expenses are borne by the issuer, including certain legal fees.

• Cash exercise of the Series C warrant in full could yield approximately $99M gross; exercise timing is uncertain and the warrant may not be exercised.

• Proceeds from the initial transaction and any further warrant exercises are intended for working capital, capital expenditures, product development and general corporate purposes, without specified allocations.